MEDIVIR, FINANCIAL STATEMENT, 1 January - 31 December 2004

• Medivir’s new issue was fully subscribed in June, raising the company SEK 322.5 m before deducting issue costs. • In July, Medivir and Biovitrum entered a research collaboration on type 2 diabetes. • In late November, Medivir signed a licensing and collaboration agreement in the hepatitis C (protease) segment with Tibotec Pharmaceuticals Ltd., a Johnson & Johnson group company. • GSK (GlaxoSmithKline) concluded its research collaboration with Medivir on the HIV compound MIV-210 in late December. Medivir will now take this project onwards in phase IIa studies. • Net sales in the Group amounted to SEK 82.6 m (previous year SEK 63.9 m excluding CCS and SEK 149.0 m including CCS). • The Group’s operating profit amounted to SEK -125.0 (-112.3) m and the net profit after tax were SEK -110.5 m (previous year of SEK -40.3 m including gains of SEK 63.4 m from the divestiture of CCS). Earnings per share were SEK -10.29 (-4.69). FOR MORE INFORMATION, PLEASE CONTACT Rein Piir, CFO and VP, Investor Relations: +46 (0)70 853 7292. FORTHCOMING FINANCIAL INFORMATION The Three-month Interim Report will be published on 21 April 2005. The Annual General Meeting will be held on 21 April 2005, from 3 p.m. The Six-month Interim Report will be published on 7 July 2005. The Nine-month Interim Report will be published on 26 October 2005. Medivir’s financial reports are available from its Website, www.medivir.se from these dates, under the ‘Financial Information’ heading.